Ye et al. proposed that targeting SRC could be a strategy to overcome resistance to treatment based on epidermal growth factor receptor (EGFR) and tyrosine kinase inhibitors in aryl hydrocarbon receptor-activated NSCLC [31]. Here, EGFR is linked to non-small cell lung carcinoma.